

DOCKET NO.: CELL-0293/PA523-USW01
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Daniel Christopher Brookings, et al.

Confirmation No.: 6765

Application No.: 10/529,413

Group Art Unit: 1642

Filing Date: June 23, 2005

Examiner: Not Yet Assigned

For: BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS

DATE OF DEPOSIT:

September 19, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☒ Copies of reference numbers 1 - 27 listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

DOCKET NO.: CELL-0293/PA523-USW01
PATENT

- 3 -

☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: *September 19, 2005*

Jane E. Inglese

Jane E. Inglese
Registration No. 48,444

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0293/ PA523-USw01	Application No. 10/529,413
	Applicant Daniel Christopher Brookings, et al.	
	Filing Date June 23, 2005	Group 1642
	Confirmation No. 6765	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
1	Adams, J.L., et al., "p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines," <i>Progress in Medicinal Chemistry, Elsevier Sci.</i> , King, F.D., et al. (Eds.), 2001 , 38, 1-60	
2	Allen, M., et al., "Deficiency of the stress kinase p38 α results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells," <i>J. Exp. Med.</i> , 2000 , 191(5), 859-869	
3	Andresen, G., et al., "Regiochemistry in addition of grignard reagents to <i>N,N'</i> -dibenzylated 2-puriones," <i>Tetrah.</i> , 1996 , 52(40), 12979-12992	
4	Badger, A.M., et al., "Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function," <i>J. Pharmacol. & Exp. Ther.</i> , 1996 , 279(3), 1453-1461	
5	Chan, D.T., et al., "New N- and O-arylations with phenylboronic acids and cupric acetate," <i>Tetrah. Lett.</i> , 1998 , 39, 2933-2936	
6	Cohen, P., "The search for physiological substrates of MAP and SAP kinases in mammalian cells," <i>Trends Cell Biol.</i> , 1997 , 7, 353-361	
7	Dinarello, C.A., et al., "An update on human interleukin-1: from molecular biology to clinical relevance," <i>J. of Clinical Immunol.</i> , 1985 , 5(5), 287-297	
8	Doza, Y.N., et al., "Activation of the MAP kinase homologue RK requires the phosphorylation of Thr-180 and Tyr-182 and both residues are phosphorylated in chemically stressed KB cells," <i>FEBS Letts.</i> , 1995 , 364, 223-228	
9	Enslen, H., et al., "Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6," <i>J. Biol. Chem.</i> , 1998 , 273(3), 1741-1748	
10	Griswold, D.E., et al., "Pharmacology of cytokine suppressive anti-inflammatory drug binding protein (CSBP), a novel stress-induced kinase," <i>Pharmacol. Commun.</i> , 1996 , 7, 323-329	
EXAMINER		DATE CONSIDERED

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0293/ PA523-USw01	Application No. 10/529,413
		Applicant Daniel Christopher Brookings, et al.	
		Filing Date June 23, 2005	Group 1642
		Confirmation No. 6765	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	11	Hale, K.K., et al., "Differential expression and activation of p38 mitogen-activated protein kinase α , β , γ , and δ in inflammatory cell lineages," <i>J. Immun.</i> , 1999 , 162, 4246-4252	
	12	Hunter, T. (Ed.), "Protein kinase classification," <i>Methods in Enzymology</i> , 1991 , 200, 3-37	
	13	Jiang, Y., et al., "Characterization of the structure and function of a new mitogen-activated protein kinase (p38 β)," <i>J. of Biological Chem.</i> , 1996 , 271(30), 17920-17926	
	14	Kotlyarov, A., et al., "MAPKAP kinase 2 is essential for LPS-induced TNF- α biosynthesis," <i>Nature Cell Biol.</i> , 1999 , 1, 94-97	
	15	Lam, P.Y.S., et al., "Copper-catalyzed general C-N and C-O bond cross-coupling with arylboronic acid," <i>Tetrah. Lett.</i> , 2001 , 3415	
	16	Lee, J.C., et al., "Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors," <i>Annals N.Y. Acad. Sci.</i> , 1993 , 696, 149-170	
	17	Lee, J.C., et al., "Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002," <i>Int. J. Immunopharm.</i> , 1988 , 10(7), 835-845	
	18	Lee, J.C., et al., "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis," <i>Nature</i> , 1994 , 372, 739-746	
	19	McDonnell, P.C., et al., "Localization of the human stress responsive MAP kinase-like CSAIDs binding protein (CSBP) gene to chromosome 6p21.3/21.2," <i>Genomics</i> , 1995 , 28, 301-302	
	20	Sont, J.K., et al., "Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue," <i>Am. J. Respir Crit. Care Med.</i> , 2003 , 167, 1496-1503	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0293/ PA523-USw01	Application No. 10/529,413
		Applicant Daniel Christopher Brookings, et al.	
		Filing Date June 23, 2005	Group 1642
		Confirmation No. 6765	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	21	Subauste, M.C., et al., "Infection of a human respiratory epithelial cell line with rhinovirus," <i>J. Clin. Invest.</i> , 1995 , 96, 549-557	
	22	Takekawa, M., et al., "A family of stress-inducible GADD45-like proteins mediated activation of the stress-responsive MTK1/MEKK4 MAPKKK," <i>Cell</i> , 1998 , 95, 521-530	
	23	Teran, L.M., et al., "Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma," <i>Am. J. Respir. Crit. Care Med.</i> , 1997 , 155, 1362-1366	
	24	Turner, R.B., et al., "Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds," <i>Clin. Infect. Dis.</i> , 1998 , 26, 840-846	
	25	Zhu, Z., et al., "Rhinovirus stimulation of interleukin-6 in vivo and in vitro," <i>J. Clin. Invest.</i> , 1996 , 97(2), 421-430	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0293/ PA523-USw01	Application No. 10/529,413
	Applicant Daniel Christopher Brookings, et al.	
	Filing Date June 23, 2005	Group 1642
	Confirmation No. 6765	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	26	WO 99/64400 A1	12/16/99	PCT		
	27	WO 03/033502 A1	04/24/03	PCT		

EXAMINER

DATE CONSIDERED